[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![BluntForceOpt Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1651613086602899457.png) BluntForceOptions [@BluntForceOpt](/creator/twitter/BluntForceOpt) on x XXX followers
Created: 2025-07-10 03:42:39 UTC

ICYMI: $MRK is acquiring $VRNA for $10B to add Ohtuvayre, the first new inhaled COPD maintenance therapy in 20+ yrs.

Smart move, IMO. Keytruda goes off-patent in 2028, and Merck faces a significant rev decline. They’ve already spent $11B on Prometheus (IBD) and $680M on Harpoon (oncology). Now they’re adding a respiratory franchise with an approved product and strong uptake.    

This is Merck buying time... diversifying fast and stacking commercial launches ahead of biosimilar pressure.

![](https://pbs.twimg.com/media/Gvd31DZakAMJwVh.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1943153871163134454/c:line.svg)

**Related Topics**
[approved](/topic/approved)
[$680m](/topic/$680m)
[$11b](/topic/$11b)
[rev](/topic/rev)
[$10b](/topic/$10b)
[$vrna](/topic/$vrna)
[$mrk](/topic/$mrk)
[stocks healthcare](/topic/stocks-healthcare)

[Post Link](https://x.com/BluntForceOpt/status/1943153871163134454)